Nanotherapeutics, Inc., a secretly hold biopharmaceutical company, announced which it has acquired in bankruptcy proceedings two late theatre clinical programs: Ramoplanin from Oscient Pharmaceuticals Corporation as well as PRX-3140 from EPIX Pharmaceuticals, Inc. Ramoplanin - an oral antibiotic for a diagnosis of Clostridium difficile-associated mildew (CDAD) - is entering Phase 3 trials...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment